POC

SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego

Retrieved on: 
Monday, April 8, 2024
Diagnosis, DOI, Cohort (statistics), Patient, SAN, Artificial intelligence, Cancer, PTM, Doctor of Philosophy, MD, AACR, POC, Blood, Probability, Medical imaging

SAN DIEGO, April 8, 2024 /PRNewswire/ -- SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, today announced three additional validation studies that evaluate OncoSeek's ability to detect more than nine cancer types and predict the tissue of origin with a tube of blood. The data further validate the performance of OncoSeek with consistent results between the three new cohorts and the three previous cohorts of ~12,000 participants from China, the United States and Brazil. The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms. The findings were presented at the session entitled 'Multi-Cancer Early Detection Testing: Where Are We?' at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the most significant oncology conferences highlighting the work of the best minds in cancer research from institutions all over the world.

Key Points: 
  • The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms.
  • The findings were presented at the session entitled 'Multi-Cancer Early Detection Testing: Where Are We?'
  • at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the most significant oncology conferences highlighting the work of the best minds in cancer research from institutions all over the world.
  • With the demonstrated performance of OncoSeek on retrospective and prospective cohorts, SeekIn is pursuing additional prospective studies to evaluate performance in different applications.

Portable Microfluidic Biofluid Analyzer Patents Available on the Ocean Tomo Bid-Ask Market® Platform

Retrieved on: 
Friday, April 5, 2024
Breast milk, Dentistry, Microfluidics, Patient, Weight loss, Biomarker, Fertility, Pregnancy, Saliva, Urine, IP, POC, Collection, Auction

CHICAGO, April 5, 2024 /PRNewswire-PRWeb/ -- Ocean Tomo, a part of J.S. Held, announces the auction of a Portable Microfluidic Biofluid Analyzer Patents, available as Lot 187, on the Ocean Tomo Bid-Ask Market® platform.

Key Points: 
  • Held, announces the auction of a Portable Microfluidic Biofluid Analyzer via the Ocean Tomo Bid-Ask Market® platform, supporting patent brokerage, patent auctions and patent transactions.
  • CHICAGO, April 5, 2024 /PRNewswire-PRWeb/ -- Ocean Tomo, a part of J.S.
  • Held, announces the auction of a Portable Microfluidic Biofluid Analyzer Patents, available as Lot 187 , on the Ocean Tomo Bid-Ask Market® platform.
  • To request bidder credentials or to receive further information on this portfolio available on the Ocean Tomo Bid-Ask Market® platform, contact Layna Guo at [email protected] or +1 312 327 8179.

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, SAN, Tissue, News, Business development, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, CONVERGE, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

Foresight: Eye-Net and Softbank Corp. Successfully Complete Technology Validation Phase for Connected Mobility Applications in Japan

Retrieved on: 
Friday, March 22, 2024
MEC, LTE, SoftBank Group, Ness Ziona, POC

Ness Ziona, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision solution, announced today that its wholly owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), announced today that SoftBank Corp. (Tokyo: 9434) (“SoftBank”) will collaborate with its business partners to initiate commercial validation efforts of Eye-Net's products in Japan following the successful completion of Eye-Net’s technology validation.

Key Points: 
  • The technological POC was confirmed to be successful after the Eye-Net Protect product met all of Softbank's predefined key performance indicators.
  • The testing confirmed the system performance and full compatibility with both long-term evolution (LTE) and 5G cellular networks, paving the way for connected mobility applications.
  • “We are thrilled that SoftBank has confirmed the successful completion of the technology validation phase and the compatibility of Eye-Net’s technology for both LTE and 5G cellular networks.
  • This milestone marks the beginning of collaborative efforts with SoftBank for commercial validation of Eye-Net’s products in Japan," said Dror Elbaz, CEO of Eye-Net Mobile.

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Retrieved on: 
Wednesday, March 20, 2024
Zealand Pharma, Plasma, Rat, LC-MS/MS, Short bowel syndrome, Half-life, Inflammation, Patient, Tablet, Teduglutide, POC, OPKO Health, Injection, Entera, Pharmaceutical industry

The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.

Key Points: 
  • The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.
  • Currently, the only approved GLP-2 agonist, which is marketed under the name Gattex® (teduglutide), requires daily sub-cutaneous injections.
  • Entera and OPKO completed a proof of concept (PoC) single dose pharmacokinetic study in rodents as the first validation for oral administration of the GLP-2 treatment.
  • This data is consistent with previously reported PK data relating to OPKO’s GLP-2 peptide’s long acting profile, which had initially been developed as a weekly subcutaneous injection.

Foresight: Eye-Net Secures Follow-up Order from Leading Japanese Vehicle Manufacturer

Retrieved on: 
Tuesday, March 19, 2024
Communication, ADAS, POC, Safety, Tier 1, Tier 2, Movement

Ness Ziona, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that its wholly-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), has received an additional order for a paid development project from a leading global Japanese vehicle manufacturer, following the successful completion of the first two phases of a paid proof-of-concept (POC) project.

Key Points: 
  • The successful completion of that phase is a significant milestone, demonstrating the feasibility and potential benefits of Eye-Net's technology for the automotive industry.
  • In this phase, the vehicle manufacturer will assess the potential of Eye-Zone™ to act as key infrastructure for point-to-point transmission of safety messages between the vehicle and designated users in the same vicinity.
  • This unprecedented capability will potentially facilitate seamless communication between vehicles and all road users and help, in particular, vulnerable road users.
  • Eye-Zone™ is Eye-Net’s Linux-based solution, offering Eye-Net’s unique V2X technology for the automotive industry (vehicle manufacturers and Tier One and Tier Two suppliers).

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
Monday, March 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Thursday, March 14, 2024
Principal, Ethanol, Collateral damage, Disease, Nervous system, Patient, POC, Pancreatic cancer, Clinical trial, Pain, AMIX, Medical imaging

THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the safe completion of the first three patient procedures for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to have safely completed the first patient procedures utilizing RF ablation in a transvascular approach to reduce the pain associated with pancreatic cancer.
  • The Principal Investigator was able to navigate the catheter to the target treatment area and perform the specified ablations with no significant adverse events.
  • The primary objective of the PoC human clinical trial is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
NMIBC, Research, BCG, LM, Bacillus, Patient, LMS, Cancer, Investment, Therapy, Injection, POC, Carcinoma, CIS, Food, Pharmaceutical industry

As of December 31, 2023, cash, cash equivalents, and investments in marketable debt securities totaled $65.6 million.

Key Points: 
  • As of December 31, 2023, cash, cash equivalents, and investments in marketable debt securities totaled $65.6 million.
  • The fourth quarter and full year increases were primarily due to an increase in expenses related to clinical trials and non-clinical activities for TARA-002.
  • Net loss for the fourth quarter of 2023 included approximately $1.5 million of stock-based compensation expenses.
  • Net loss for the year ended December 31, 2023 included approximately $6.1 million of stock-based compensation expenses.

Global Mobile Medical Imaging Market Trends and Growth Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 4, 2024
Radiology, Health, Medical Devices, Row, COVID-19, Privacy, Computer security, Telehealth, POC, Medical device

The "Global Mobile Medical Imaging Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Mobile Medical Imaging Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The report focuses on mobile imaging equipment for POC settings, enabling bedside imaging and remote diagnosis (excluding conventional, trailer-mounted mobile imaging equipment that users must transport to different locations).
  • There is a growing demand for mobile imaging equipment in low and middle-income countries due to the limited financial resources to procure, operate, and maintain expensive medical imaging equipment.
  • This study will provide the trends, challenges, drivers, restraints, competitive landscape, and growth opportunities for mobile medical imaging systems in different clinical settings, including at-home medical imaging and remote diagnosis.